How to use Delta sleep-inducing peptide hormone

Outrageous mind theft on the most perverse LEVEL ... everything can be found in my patents ... "ET"

Fort Detrick - A previously unknown "broad-spectrum inhibitor" of filoviruses has suppressed the replication of Ebola and several other viruses in laboratory experiments. Rhesus monkeys could be protected from fatal Ebola even in the viraemic phase if the results presented at IDWeek 2015 in San Diego are correct.

Ebola is, with the exception of one mistake, a group does not exist! Check your syntax! (ID: 2) Disease in Great Britain, gone from the headlines. At the beginning of October, the World Health Organization reported that, for the first time since March 2014, there had been no new Ebola cases in

West Africa became known. The danger is not averted, and an active ingredient that is effective after the onset of the disease is still missing. The Californian company Gilead Sciences could now have found such an active ingredient.

According to the company, the substance GS-5734 is a "broad spectrum inhibitor" of filoviruses. Strictly speaking, it is a prodrug that is administered intramuscularly and which, after entering the cells, becomes a nucleotide analog. GS-5734 has, if the data presented at the conference can be believed - a publication is still pending - an astonishingly broad effect against filoviruses.

In cell cultures, the active ingredient was not only active against Ebola viruses (Kikwit and Makona variants). The replication of Lassa virus, MERS virus and Marburg virus was also inhibited. This is amazing as only the Marburg virus belongs to the same family as the Ebola virus. The common denominator to the other viruses is that they all belong to the single (-) - strand RNA viruses.

At a high security laboratory of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) were treated intramuscularly with 3 mg / kg GS-5734 in a first series of rhesus monkeys on days 2 through 4 after inoculation of the virus. Every second animal survived, while in the placebo arm all animals perished. In a second series, the dose was increased to 10 mg / kg and administered intravenously. As Travis Warren of USAMRIID in Fort Detrick, Maryland reports, all animals treated with GS-5734 survived this time. The virus concentration was decreased by 5 log10 copies / ml. In addition, the first clinical signs of Ebola disease such as thrombocytopenia, coagulation disorders and the chemical laboratory values ​​improved.

A representative of the manufacturer announced that phase 1 studies have already started. In them, the broad-spectrum inhibitor is first tested on healthy volunteers. Whether it will also be used on patients after passing this test will likely depend on the further course of the current epidemic. According to the latest WHO figures, 28,457 people have fallen ill since the outbreak in Guinea, Liberia and Sierra Leone, of which 11,312 have died. ©rme / aerzteblatt.de

FRIENDS,

depraved society, depraved science, intellectual property rob these vultures and pass it off as theirs .... the CREATOR will punish YOU, 666 minus, ZION SATANISTS, hard for it, very hard !!

This knowledge has been found FOR LIFE, but these robbers and murderers of those named use it AGAINST LIFE ... !!

Document identificationDE202006001133U1 11/23/2006
titleMultifunctional mixture of active ingredients with preventive and therapeutic properties for use as a universal adjuvant for the production of vaccines against viral and cancer diseases
Applicant Tech, Egon, 18147 Rostock, DE
Representative Baumbach, F., Dr.rer.nat. Pat.-Ing., Pat.-Ass., 13125 Berlin
DE file number 202006001133
Date of advertisement in the Patent Gazette23.11.2006
Registration date 19.10.2006
Application date from patent application